Moderna

Biotech company Moderna, which is testing one of the leading coronavirus vaccine candidates, priced an offering of 17.6 million new shares at $76 each, the company said late Monday.The company said it expects the offering to close around Thursday, with gross proceeds totaling around $1.34 billion. Moderna is also giving the underwriters a 30-day option to buy…

Moderna Inc., a Massachusetts-based biotech company, on Monday reported positive interim data in the first phase of a coronavirus vaccine trial, saying some patients who were vaccinated developed antibodies at levels mirroring recovered COVID-19 patients. The Phase 1 study included 45 people ages 18-55. The study was split so that 15 participants took a low…

Moderna's closely watched early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants, the biotech company announced Monday, sending the company's shares surging 30% in premarket trading.Each participant received a 25, 100 or 250 microgram dose, with 15 people in each dose group. Participants received two doses of the potential vaccine via…

Between the company’s powerful therapeutics development platform, a star-studded roster of collaborators, and promising early phase trials, Moderna is poised for success. Moderna's (NASDAQ:MRNA) stock has been a fast-mover in the last few weeks as a result of the company's COVID-19 vaccine efforts, funded to the tune of $483 million by the U.S. government. Investors…

Moderna Inc. (NASDAQ: MRNA) has signed an agreement for a $483 million funding from a federal agency, the biotechnology company announced Thursday. What Happened The funding from the Biomedical Advanced Research and Development Authority will help the company's novel coronavirus (COVID-19) vaccine advance through clinical trials to an approval by the United States Food and…